Figure 1. Protection against EAE development after administration of PLP_139–151 16-mer.

(A) EAE was induced in SJL/J mice with 50 µg of the encephalitogenic PLP_139–151 peptide emulsified in complete Freund's adjuvant containing Mycobacterium tuberculosis. Mice were untreated or treated intravenously with 50 µg of the PLP_139–151 16-mer on day 7 after disease induction as represented by the arrow. (B) Mice were vaccinated subcutaneously or intravenously with 50 µg of PLP_139–151 16-mer. Vaccination was performed 7 days before EAE induction as indicated by the arrow. Subcutaneous injection was given in incomplete adjuvant and for the intravenous injection the oligomer was dissolved in PBS. (C) Mice (n = 8) were treated individually once the first clinical signs of EAE appeared. 50 µg of the PLP_139–151 16-mer was given intravenously in diseased mice. The plots show the mean ±SEM daily clinical score. Statistical significance between groups was determined was determined by Mann-Whitney U test. ***P<0.001, **P<0.01 and *P<0.05 compared with respective control group.